36 results about "Plasma samples" patented technology

The invention discloses a disease risk assessment method and screening device based on a multi-group student physical collaborative digital network, and relates to the field of intelligent medical detection. In order to solve the defect that multi-omics-level system collaborative analysis and robust risk assessment are difficult to realize in the prior art, the technical scheme provided by the invention is as follows: acquiring a plasma sample, acquiring a spectral signal by adopting an attenuated total reflection Fourier transform infrared spectrum, and establishing a plasma spectrum digital information space; the method comprises the following steps: constructing a biological collaborative digital network containing four nodes of protein, lipid, saccharides and nucleic acid based on pathophysiology priori knowledge, and defining node strength, edge weight and network collaborative efficiency; a health baseline configuration file is established by using a health sample, a standardized deviation score of a to-be-tested sample is calculated, a comprehensive risk score is obtained, a disease screening result is output in combination with a machine learning model, and digital evaluation of multi-omics collaborative characteristics is realized. The method is suitable for non-invasive rapid screening and risk assessment work of neurodegenerative diseases and mental diseases.

The invention belongs to the technical field of chemical screening, and particularly relates to a systematic screening method for rubber-related chemicals in a plasma sample, which comprises the following steps: S1, taking the plasma sample, adding a mixed extraction solvent, extracting, centrifugally layering, collecting supernate, repeatedly extracting, merging the supernate, concentrating, and freezing to obtain a rubber-related chemical sample; centrifuging again, adding an isotope internal standard, and carrying out data dependence acquisition in a positive and negative ion analysis mode by adopting liquid chromatography-tandem high-resolution mass spectrometry. According to the invention, the comprehensive coverage type monitoring of 1300-1500 RDCs in the plasma sample is realized. By means of combination of a positive and negative ion double analysis mode and data dependence acquisition, the detection range and the signal response stability of the RDCs with different polarities are effectively considered, and the technical problem that in the prior art, the composite effect generated by coexistence of multiple RDCs is ignored is solved.

The application discloses a combined filter for separating plasma from whole blood, comprising a whole blood sample adding chamber, a first combined filter membrane, an intermediate chamber, a second combined filter membrane and a plasma collecting chamber arranged in sequence along a filtering direction of a whole blood sample flow; and the whole blood sample is filtered multiple times through the first combined filter membrane and the second combined filter membrane to obtain a plasma sample. The application further provides a combined filter device and a method for separating plasma from whole blood. The combined filter provided by the application can further improve the recovery rate, recovery quality and recovery efficiency of the whole blood separation plasma, and meets the demand of in-vitro diagnosis on the pretreatment of the whole blood sample.

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

The invention provides methods for simultaneously enriching multiple target regions of interest in one reaction volume, from cell-free DNA isolated from a blood or plasma sample, followed by high-thought sequencing and sequence read analysis. The invention also provides library of target-specific oligonucleotide primers or probes for the multiplexed target enrichment.

A biological sample processing device including a blood filtration module and an extraction module incorporated within a common housing. The blood filtration module has a dual filter structure. The extraction module includes a series of chambers that hold agents to effect any one or more of lysis, binding of target material to capture beads, washing, elution, and / or nucleic acid amplification. Moveable magnets are used to move the beads through the chambers to perform the extraction process. A second magnet-based device for preparing largely pure plasma samples from whole blood in the field.

The present invention provides a method of determining endometrial status using a sample (e.g., a plasma sample) from a subject, comprising: (a) performing an assay on a blood sample from a subject to determine a miRNA expression profile wherein the miRNA expression profile comprises a plurality of expression levels of miRNAs, and (b) analyzing the miRNA expression profile using a computer-based machine learning model to obtain a predicted score.

The present invention relates to a method for determining whether an unknown blood sample is a serum sample, a citrated plasma sample, or an EDTA-treated plasma sample. The invention also relates to a method for the diagnosis and / or monitoring of a patient suffering from a hemostasis disorder.

The present disclosure deals with the biochemistry of reagents useful in the detection of ammonia in liquid samples. Specifically, the present disclosure is directed to a technical improvement of an enzyme-based test for ammonia that can be used for analysis of plasma samples taken from patients in clinical settings, among other uses. In this regard, stability of a reagent containing NAD(P)H is improved, enhancing shelf life and results in the detection of ammonia. In an exemplary reagent ammonia released as a result of NAD(P)H decay is scavenged using an enzymatic reaction to convert the ammonia using GLDH, NAD(P)H and 2-oxoglutarate, thereby forming L-glutamate, NAD(P)+ and H2O in the NAD(P)H containing reagent.

The invention discloses a plasma near-infrared spectrum mode recognition method for detecting latent hepatitis B. The method comprises the following steps: S1, collecting spectral data of a plasma sample to be tested in a near-infrared band; s2, acquiring multi-repetition near infrared spectrum data of each sample, and constructing a spectrum data set; s3, grouping samples of a latent hepatitis B infection group and a normal control group in the spectral data set; s4, constructing an OBI-normal control spectrum discrimination model of the plasma sample based on a classifier primitive algorithm; s5, preprocessing parameters are optimized based on the discriminant performance of the classifier; s6, constructing an optimal wavelength combination; and S7, checking the optimal model. Compared with the prior art, the plasma near infrared spectrum mode recognition method for detecting the latent hepatitis B has the advantage that a solution can be provided for developing a small special blood analyzer for detecting latent hepatitis B infection.

The present disclosure relates to an application of gene markers in multi-cancer early detection, a method for constructing an early detection model, and a detection device. In the present disclosure, low-coverage whole-genome sequencing is conducted on cell-free DNAs (cfDNAs) from a plasma sample, and according to high-throughput sequencing results, six differential features of the cfDNA fragments are analyzed for each cancer. Then the training and modeling are conducted with a convolutional neural network to allow the early detection of a plurality of cancers at a low sequencing depth. Then the training and modeling are conducted with a generalized linear model (GLM), a gradient boosting machine, a random forest model, a deep learning model, and an extreme gradient boosting model, and staking is conducted with a GLM to construct a multi-feature algorithm, to allow the tissue-of-origin-based detection of cancers.

The application discloses polypeptide markers based on autoantibodies and application thereof in early lung cancer diagnosis, and relates to the technical field of biological detection. The application finds that there are 143 polypeptide probes with significant signal differences between a lung adenocarcinoma group in early stage and a healthy population group through research and analysis of plasma samples of the two groups, and further screens 14 polypeptide probes that can produce more stable signal differences between the two groups. Through attempts of various machine learning methods, it is found that a classification model can be established by taking the signal value accumulation of the 14 polypeptide probes as an index for model construction, thereby providing a path for effective diagnosis of early lung adenocarcinoma.

The disclosure discloses a method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel and a method for determining the same, which belongs to the technical field of pharmaceutical analysis and solves the problem in the prior art that there is not yet a method for determining the concentration of (7aS,2′S)-2-oxo-clopidogrel in plasma. The method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel comprises: taking whole blood containing (7aS,2′S)-2-oxo-clopidogrel, adding a reducing agent solution and collecting plasma. The method for determining (7aS,2′S)-2-oxo-clopidogrel in plasma according to the disclosure uses the treatment method as described above to treat a sample to be determined, and includes the following steps: S1. Whole blood treatment: taking whole blood, adding a reducing agent solution, centrifuging, and collecting plasma; S2. Plasma sample pre-treatment: adding a protein precipitant and an internal standard working solution to the plasma, vortexing and then centrifuging, and taking the supernatant; S3. LC / MS / MS determination. The method of the disclosure is simple, easy to operate, and has good stability, specificity and sensitivity, and accurate determination results.

A system for collecting menstrual blood and vaginal secretions for diagnostic and health monitoring purposes, and more particularly, to a system for providing absorbent materials, such as female sanitary pads and urinal pads, with a strip or patch for collecting bodily fluids, providing a container comprising a desiccant for transporting and storing the collected sample to a laboratory, dried menstrual blood samples (DMS), dried menstrual blood plasma samples (DMPS), dried blood spots (DBS), and / or dried blood plasma spots (DPS) are analyzed in a laboratory, or some of the containers without desiccant can maintain sufficient hydration to maintain the collected cells intact, for analysis using methods such as DNA testing, slide-based analysis, or cell culture, for example, for use in the field of laboratory analysis of dried menstrual blood samples (DMS), dried menstrual blood plasma samples (DMPS), dried blood spots (DBS), and / or dried blood plasma spots (DPS), or some of the containers without desiccant can maintain sufficient hydration to maintain the integrity of the collected cells. Various collection strip structures are provided that can be used for menstrual blood and vaginal secretions and for collecting and / or separating venous blood and capillary blood, as well as functional pad design elements to aid in sample collection, retention of collection strips, and to facilitate high speed manufacturing of pads.

The invention discloses an aptamer-mediated EXPARs-molecular beacon fluorescent biosensor as well as a preparation method and application of the aptamer-mediated EXPARs-molecular beacon fluorescent biosensor. The construction and detection process of the sensor comprises three key steps: protein binding aptamer, exponential isothermal amplification (EXPAR) and molecular beacon fluorescence resonance energy transfer (FRET). Through the ingenious design of the EXPAR system, the system realizes triple signal amplification, the detection sensitivity is remarkably improved, and Abeta42 and Abeta40 amyloid proteins as low as 100fM level can be detected. Besides, based on the sequence specificity of the aptamer and the highly specific design of each nucleic acid sequence involved in the detection system, the method can be used for simultaneously detecting the Abeta42 amyloid protein and the Abeta40 amyloid protein or other substances in the same system (such as a plasma sample), so that the detection efficiency is improved.

Devices, assemblies, and kits are disclosed for separating and / or metering a plasma sample from a patient's liquid test sample. Also disclosed are methods of producing and using same.

The utility model relates to the technical field of medical instruments, in particular to a sample placing tray for a plasma electrolyte detector, which comprises a base, the plasma electrolyte detector and a tray, the plasma electrolyte detector and the tray are placed on the base, a driving disc is mounted in the tray, a clamping component for placing a test tube is arranged on the driving disc, and the clamping component is arranged on the base. A first rack is slidably connected into the material disc, an ejector rod is connected to the top of the first rack and penetrates through the driving disc to make contact with the clamping assembly, a gear is rotatably connected into the material disc, a pressing plate is slidably connected to the outer ring of the material disc, the part, located in the material disc, of the pressing plate is connected with a second rack, and the first rack and the second rack are located on the two sides of the gear correspondingly and engaged with the gear. And a second reset spring is arranged between the second rack and the charging tray. Through cooperation of a clamping plate, a guide rod and a first reset spring in the clamping assembly, the plasma sample test tube is stably clamped, the clamping device automatically adapts to test tubes of different sizes through the elastic force of the spring, and the clamping compatibility and flexibility are improved.

The invention discloses an early tumor detection method and system based on DNA characteristics, and relates to the technical field of molecular diagnos.By setting standardized time sequence sample collection nodes and synchronously collecting plasma samples at multiple time points, it is ensured that the dynamic process of DNA steady-state change can be captured, and in the aspect of sample treatment, the detection accuracy is improved. The method comprises the following steps: extracting cfDNA by adopting a paramagnetic particle method automatic extraction technology, setting a strict quality control standard, ensuring the quality of a detection sample, constructing an integrated cross-interference-free mixed reaction system, and synchronously capturing oxidative damage markers and methylation modification in the cfDNA by using a specific probe, so that synchronous detection of a two-dimensional molecular marker is realized; accurate two-dimensional time sequence signal data are obtained through a two-channel fluorescence synchronous detection and internal reference correction technology, a normal physiological dynamic reference model is constructed, and based on the model, accurate judgment of the early risk of the tumor is achieved by calculating a time sequence characteristic deviation value.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to complement protein C8 gamma-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).

The present disclosure finds that TGFBI in a plasma sample can serve as a diagnostic molecular marker for primary biliary cholangitis, provides a molecular marker and diagnostic model with high specificity and high sensitivity for individualized diagnosis and treatment of primary biliary cholangitis, and provides a new, efficient and non-invasive auxiliary tool for the clinician to formulate a diagnostic scheme for primary biliary cholangitis.

The utility model relates to the field of medical treatment, in particular to a plasma sample detection device which comprises a plasma detector, a display screen and a collecting mechanism, the display screen is assembled on the plasma detector and used for displaying detection results, and the collecting mechanism for placing medical articles is arranged on the plasma detector. An operator lifts a handle upwards, a first spring of the handle is compressed, meanwhile, the handle rotates on a fixing block and does not make contact with a storage box, a second spring stretches to drive the storage box to move towards the outer side, and then the operator places medical articles in the storage box, so that the effect of conveniently placing the articles in a classified mode is achieved; and the effect of improving the operation convenience of an operator during use is achieved.

The invention provides methods for simultaneously enriching multiple target regions of interest in one reaction volume, from cell-free DNA isolated from a blood or plasma sample, followed by high-thought sequencing and sequence read analysis. The invention also provides library of target-specific oligonucletotide primers or probes for the multiplexed target enrichment.

Methods and systems disclosed herein can improve the quality of blood-derived samples (e.g., whole blood, serum, or plasma sample). In an aspect, the present disclosure provides a method of evaluating a plasma sample quality, comprising collecting a blood sample from a subject; processing the blood sample to separate a plasma sample from other blood components; quantitatively measuring amounts of one or more analytes present in the plasma sample, wherein the one or more analytes comprise hemoglobin, potassium (K), lactate, or formaldehyde (CH2O); and evaluating the quality of the plasma sample based at least in part on the measured amounts, wherein the measured amounts are indicative of the plasma sample quality. In another aspect, the present disclosure provides a method of adjusting for preanalytical bias utilizing a linear regression model to improve a signal to noise ratio, thereby potentially enhancing the performance of a classification model.

The utility model relates to a feeding device, in particular to a sample feeding device of a plasma detector, which comprises the plasma detector, a moving arm, a suction pipe, an electric slide rail and a movable plate, the moving arm is arranged on the plasma detector, the suction pipe is arranged on the moving arm, and the moving arm can drive the suction pipe to move up and down. The suction pipe can suck a plasma sample in the test tube and then drop the plasma sample on a detection position, and an electric sliding rail is installed at the bottom of the moving arm. The suction tube is driven by the moving arm to move, when a plasma sample needs to be sucked or dripped out by the suction tube, the movable plate and the collecting box can be driven by the electric sliding rail to move away from the lower portion of the suction tube, movement of the suction tube in the vertical direction is not affected, and after the suction tube moves upwards and resets, the suction tube can be separated from the collecting box. The electric sliding rail can drive the movable plate and the collecting box to move forwards, so that the collecting box is positioned below the suction tube, and the plasma sample attached to the outer wall of the suction tube is prevented from dropping on a table top or other test tubes, so that the influence on the accuracy of detection data due to mixed detection is avoided.

The invention provides a dual-nucleic acid library co-construction method for synchronous detection of plasma ecDNA and related RNA markers. The method comprises the following steps: firstly, extracting total free nucleic acid from the same plasma sample; then carrying out linear DNA digestion treatment; then removing ribosome RNA (Ribose Nucleic Acid); then carrying out reverse transcription reaction by using a chimeric primer with 6-9 random basic groups at the 3'end and a template conversion oligonucleotide sequence at the 5 'end to obtain single-stranded cDNA with universal joints at the two ends; next, the single-stranded cDNA is subjected to cyclization, and annular cDNA is formed; then carrying out rolling circle amplification on the ecDNA and the annular cDNA; and carrying out fragmentation, terminal repair, linker connection and PCR enrichment on the amplification product to obtain the dual-nucleic acid library for high-throughput sequencing. By adopting the method, the collaborative analysis of the DNA level and the RNA level of the trace sample is realized.

The utility model provides a separating device for plasma samples, which comprises a bottom plate, a channel plate and a top plate, a plasma channel is arranged on the channel plate, the bottom plate and the top plate respectively cover the upper surface and the lower surface of the channel plate to seal the plasma channel on the channel plate, and at least one interception area is arranged on the plasma channel. The plasma separating device is low in manufacturing and using cost, small in size and convenient to carry and use, does not need to be provided with a centrifugal machine, and can be used for separating plasma in time in areas with underdeveloped or underdeveloped medical resources or grassroots and under the emergency conditions that no electric power resource exists or electric power is in shortage or is stopped. The plasma separating device disclosed by the utility model has expandability, can be connected in parallel to form a multi-channel mode to timely process a large-dose blood sample when necessary, can also perform expandability of targeted transformation, and can be used for primarily judging whether abnormal cells exist in blood or not, such as whether macrophages and cancer cells are increased or appear or not; and preliminary judgment of corresponding indexes can be assisted.

To provide a novel assay and / or platform for measuring functional C1-INH involved in HAE disease pathology.SOLUTION: A device and a lateral flow assay (LFA) method performed using such device is a device for detecting and / or quantifying functional C1-esterase inhibitor (fC1-INH), including: (i) a conjugate pad comprising a first zone and a second zone in which a first agent and a second agent are immobilized, respectively; and (ii) a membrane in communication with the conjugate pad, in which the membrane includes a third zone in which a third agent is immobilized.SELECTED DRAWING: Figure 4

This invention provides the application of β2-microglobulin in the preparation of products for diagnosing and / or prognostically assessing acute exacerbations of COPD, relating to the field of biotechnology. This invention detects the level of β2-microglobulin in plasma samples of subjects, showing that the level of β2-microglobulin in plasma samples from patients experiencing acute exacerbations of COPD is significantly upregulated compared to healthy controls. This invention also follows up patients with acute exacerbations of COPD for one year after discharge, statistically analyzing relapse rates and survival. Patients are divided into high-value and low-value groups based on their β2-microglobulin levels at enrollment. Multivariate analysis shows that low concentrations of β2-microglobulin are an independent risk factor for recurrent acute exacerbations in patients with end-stage COPD. The experimental results of this invention suggest that β2-microglobulin has diagnostic and prognostic value in acute exacerbations of COPD.

The invention discloses a marker and a probe composition for early diagnosis of gastric cancer and application of the marker and the probe composition. The marker is an ST8SIA1 gene and / or an SPAG4 gene. According to the present invention, with the application of the marker, the methylation state of the gene can be sensitively and specifically detected so as to be used for the detection of the DNA of the plasma sample of the gastric cancer patient, and the composition is used for the screening of the asymptomatic population in the non-invasive manner so as to reduce the harm caused by the invasive detection, and further improve the detection efficiency. The composition has higher sensitivity and accuracy, and can realize real-time monitoring.